Cutting Edge Anti-Aging Physician Joins Samaritan Scientific Advisory Board; Dr. Julio Garcia, M.D., Joins Scientific Advisory Board.Business Editors, Health/Medical Writers LAS VEGAS--(BUSINESS WIRE)--Jan. 17, 2003 Samaritan Pharmaceuticals Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :SPHC) and Samaritan Research Labs, Georgetown University, announced the addition of Dr. Julio Garcia to its highly esteemed Scientific Advisory Board. Dr. Garcia joins chair Dr. Papadopoulos, of Georgetown University, Dr. Tillement of University of Paris, France, Dr. Saldi of Fremont Clinics, Nevada, Dr. Varese, International anti-aging pioneer, and various informal scientific advisors. Samaritan's Scientific Advisory Board is involved in both new drug discovery and the clinical aspects of patient trials. Dr. Garcia is a graduate of the University of Illinois University of Illinois may refer to:
Group of architects and engineers who in the 1890s exploited the twin developments of structural steel framing and the electrified elevator, paving the way for the ubiquitous modern-day skyscraper. of Medicine, and is a well regarded board certified board certified, adj the status of a dental specialist such as an orthodontist who has become a board diplomate by successfully completing the certification program of the recognized certification board in that area of practice. plastic surgeon and anti-aging expert in Las Vegas, NV. His scientific publications related to Samaritan's work include "Reconstructive Surgery for Immuno-suppressed Organ-Transplant Recipients" and "Cancer Immunology Immunotherapy." Dr. Garcia has focused on anti-aging for numerous years and has gained media attention with interesting topics, such as, "Just Say No, Joe - Coffee and Its Effect on Aging", "Does Body Weight Affect Our Cancer Risk?" and "Don't Let the Sands of Time This article is about the magic Sands from the Prince of Persia: The Sands of Time trilogy. For other uses, see Sands of Time (disambiguation). In the Prince of Persia: The Sands of Time video game trilogy, the Sands of Time Drop Through Your Hands, Anti-Aging Medicine - A Preventative Approach." Dr. Janet Greeson, Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. stated, "We are fortunate that Dr. Garcia has decided to bring his skills and experience with anti-aging to Samaritan. His research interests include the conducting of clinical trials and the prevention of nuero-degenerative diseases such as Alzheimer's." About Samaritan Pharmaceuticals Samaritan Pharmaceuticals, in collaboration with Georgetown University, strives to commercialize breakthrough scientific innovation. Samaritan is focused on the development of novel therapeutics for Alzheimer's, CNS See Continuous net settlement. CNS See continuous net settlement (CNS). Disorders, Cancer, Cholesterol and HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . Samaritan's patented pipeline includes: a completed HIV Phase II trial with positive data being prepared for FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. submission; an Animal (rat) model for Alzheimer's disease; Novel Neuroprotective compounds; a Peptide to bind cholesterol; an Alzheimer's and Breast Cancer Diagnostic/Theranostic; and a series of novel compounds. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 26, 2002. The company undertakes no duty to update forward-looking statements. To receive future press releases and newsletters automatically, or for more information, visit our Web site at www.samaritanpharmaceuticals.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion